Klarskov P, Holm-Bentzen M, Nørgaard T, Ottesen B, Walter S, Hald T
Department of Urology, Herlev Hospital, Denmark.
Br J Urol. 1987 Aug;60(2):113-8. doi: 10.1111/j.1464-410x.1987.tb04944.x.
Three human studies were performed to evaluate the influence of vasoactive intestinal polypeptide (VIP) on bladder and urethral function. Bladder neck smooth muscle biopsies were obtained from nine men with functional bladder neck obstruction, from 10 men with medium sized benign prostatic hypertrophy and from four patients with a normal infravesical outlet. The biopsies were analysed for VIP by radioimmunoassay and by immunohistochemistry. No differences were found between the groups. Pressure-flow-EMG studies were performed in five men and urethrocystometry was performed in six women at rest, repeated coughing and at squeezing before, during and after VIP 3 micrograms/kg X h intravenously. No systematic changes developed in any of the urodynamic parameters.
进行了三项人体研究，以评估血管活性肠肽（VIP）对膀胱和尿道功能的影响。从9名功能性膀胱颈梗阻男性、10名中度良性前列腺增生男性和4名下膀胱出口正常的患者身上获取膀胱颈平滑肌活检组织。通过放射免疫分析和免疫组织化学对活检组织进行VIP分析。各组之间未发现差异。对5名男性进行了压力-流-肌电图研究，对6名女性在静息状态、反复咳嗽时以及静脉注射3微克/千克×小时VIP之前、期间和之后进行挤压时进行了尿道膀胱测压。任何尿动力学参数均未出现系统性变化。
